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OBJECTIVE: To analyze the relationship between comorbid
conditions and direct treatment costs for patients diagnosed with
migraine in the Taiwan’s National Health Insurance (NHI)
system. METHODS: Retrospective analyses on continuously
enrolled Individuals diagnosed as having migraine from July 1,
2000 to December 31, 2002 (with 6 months run-in periods and
1-year follow up period) are employed in a NHI claims data-
bases. New migraineurs were identiﬁed on the basis of ICD-9-
CM codes, and direct treatment costs were calculated using
Taiwan NHI payments for migraine related medical events by
type of medical care. Data on the cost of outpatient care, med-
ications, and inpatient care were collected. Comorbid conditions
were based on the diagnostic classiﬁcations from the Charlson
comorbidity index. The log-transformed direct costs were ana-
lyzed by multivariate techniques. Control variables included
demographics, type of providers, comorbidities, and follow up
periods. RESULTS: Of 24,801 remained patients for study, there
are 21,924 (88.4%) migraine alone and 2,877 (11.6%) migraine
with comorbid conditions. The differences between migraine
with comorbid conditions and migraine alone in total mean costs
per patient were NTC2284 during the study period (NTC3737
vs. 1453; p < 0.001). Higher prescription drug costs of
NTC1521, higher physician visit costs of NTC581 accounted 
for most of the difference. The differences in total mean costs
per patient for migraine with comorbid conditions relative to
migraine alone patients were higher for the 8 most prevalent
comorbidities. Higher costs were attributable to higher pre-
scription drug and physician visit utilization. However, differ-
ences varied across conditions, ranging from NTC6759 in higher
costs for diabetes with chronic complications to NTC156 in
higher costs for myocardial infraction. CONCLUSIONS: These
results demonstrate costs differences were smaller for acute con-
ditions such as myocardial infraction compared with chronic dis-
eases among comorbid conditions for patients diagnosed with
migraine.
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OBJECTIVE: To determine the cost-effectiveness of six triptans
in the acute treatment of migraine based on number needed to
treat (NNT) and doses needed to treat (DNT) derived from data
in a published meta-analysis combined with the wholesale acqui-
sition cost (WAC). METHODS: Efﬁcacy and recurrence data
were obtained from a meta-analysis of 53 randomized, double
blind, controlled (placebo or active comparator) trials of triptan
use in adult outpatients (Ferrari 2001). Triptans studied were:
almotriptan 12.5mg (A12.5), eletriptan 40mg (E40), naratrip-
tan 2.5mg (N2.5), rizatriptan 5mg and 10mg (R5 and R10),
sumatriptan 50mg and 100mg (S50 and S100) and zolmitriptan
2.5mg and 5mg (Z2.5 and Z5). Treatment success was measured
by sustained pain-free therapeutic gain (SPFTG), the percentage
of patients who were pain-free within 2h post-dose (placebo-
subtracted), with no headache recurrence or use of rescue med-
ication within 24h. SPFTG was calculated using the published 
2h pain-free and recurrence rates. The NNT and DNT to achieve
100 successfully treated patients were calculated; DNT were
divided by the WAC (AnalySource®, September 2003) to obtain
cost per successfully treated patient (CPSTP). RESULTS: E40
and R10 had the highest SPFTG (18% and 19%, respectively);
N2.5 (11%), S50 (13%) and R5 (13%) had the lowest. E40 and
N2.5 had the lowest recurrence rates (21% each); R5 (39%) and
R10 (37%) had the highest. E40 and R10 had the lowest DNT
(686 and 713, respectively); N2.5 (1094) and R5 (1040) had 
the highest. CPSTP was lowest for E40 ($86.69), then R10
($102.32), and was highest for N2.5 ($181.99) and R5
($149.18). CONCLUSIONS: E40 and R10 had the lowest DNT.
E40 was the most cost-effective triptan, followed by R10; N2.5
was the least cost-effective. Results are important for health care
decision-makers in the acute treatment of migraine.
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OBJECTIVES: Interferon beta-1a (Avonex®) is efﬁcacious in
delaying clinically deﬁnite multiple sclerosis (CDMS) following
a single demyelinating event (SDE). The purpose of this study
was to determine the cost-effectiveness of Avonex® compared 
to current treatment (CT) in delaying the onset of CDMS.
METHODS: A cost effectiveness analysis (CEA) was performed.
The outcome of interest was time spent in the pre-CDMS state,
termed monosymptomatic life years (MLY) gained. A Markov
model was developed with all transitional probabilities derived
from the literature. Costs were reported in 2002 Canadian
dollars. Costs and outcomes were discounted at 5%. A time
horizon of 12 years was applied. All uncertainties were tested
via univariate and multivariate sensitivity analyses. RESULTS:
From the Ministry of Health (MoH) perspective, the total
expected costs per patient were $173,000 and $108,000 for
Avonex® and CT, respectively. From the SOC perspective, the
total expected costs were $317,000 and $262,000, respectively.
Expected MLYs gained were 4.69 for Avonex® and 3.48 for CT.
The incremental cost of Avonex® per MLY gained was $53,110
from the MoH perspective and $44,789 from the SOC perspec-
tive. The model was sensitive to the probability of progressing
to CDMS and the analytical time horizon. CONCLUSION: Our
results suggest that Avonex® may be considered as a reasonably
cost-effective approach to treatment of patients experiencing a
SDE. In addition, the overall incremental cost-effectiveness
proﬁle of Avonex® improves if treatment is initiated in pre-
CDMS rather than waiting until CDMS.
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OBJECTIVE: To model the economic implications of screening
for neutralizing antibodies (NAbs) to interferon beta (IFNb) in
treatment of relapsing-remitting multiple sclerosis (RRMS).
There is considerable evidence that NAbs to IFNb can reduce its
clinical efﬁcacy. NAb incidence ranges from 28–47% with IFNb-
1b (Betaseron), 12–24% with IFNb-1a (Rebif), and 2–6% with
IFNb-1a (Avonex). Early identiﬁcation of Nab + patients may
improve cost-effectiveness of IFNb therapy. METHODS: A
Markov model was constructed to estimate and compare costs
and quality of life-related utility of IFNb therapy. Seven treat-
ment scenarios (Avonex, Betaseron, and Rebif, with and without
